Biovail Settles, Has SAC In Sights

Sep 11 2007 | 7:10am ET

The settlement between Canadian pharmaceutical maker Biovail Corp. and Banc of America Securities could be bad news for hedge fund honcho Steven Cohen and his SAC Capital Management.

Yesterday, Biovail settled its market-manipulation suit against BofA and a former analyst, saying that the deal “is expected to be extremely helpful in Biovail’s pursuit of its lawsuit” against SAC, related entities and persons, and independent research firm Gradient Analytics. But the “substantial sworn testimony” that ex-analyst David Maris is set to provide, along with possibly additional evidence from BofA, are reportedly not coming cheap: The New York Post reports that, under the terms of the settlement, Biovail will pay some $2 million to Maris and BofA to cover legal expenses.

Biovail alleges that SAC helped “ghost write” negative and false research reports about it for the furtherance of its own benefit; SAC had shorted Biovail stock in 2003 and 2004.

Both SAC and Gradient have denied any wrongdoing.


In Depth

Steinbrugge: Top 10 Hedge Fund Industry Trends for 2017

Jan 3 2017 | 9:03pm ET

Each year, Agecroft Partners' Don Steinbrugge predicts the top hedge fund industry...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

DarcMatter: The Top Trends in Alternative Investments for 2017

Jan 13 2017 | 8:22pm ET

The $7 trillion alternative investments industry is poised for continued growth...

 

From the current issue of

The U.S. Commodity Futures Trading Commission (CFTC) ordered The Goldman Sachs Group Inc., and Goldman, Sachs & Co. to pay a $120 million penalty for attempted manipulation and false reporting of ISDAFIX Benchmark Rates, a global benchmark for interest rate products.